ClinicalTrials.gg
Enrolling by invitationNCT06885372STABILITY LTFUpdated May 14, 2026

Long-term Follow up of the Stability 1 Trial

An interventional study of Lateral Extra-Articular Tenodesis (LET) and ACL Reconstruction in LET, ACL Reconstruction and Osteoarthritis (OA) of the Knee, sponsored by Western University, Canada. Enrolling by invitation at 8 sites in 2 countries. Open to participants aged 14 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Western University, Canada · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Nov 2024, registered Mar 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
510
Allocation
Randomized
Ages
14 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 205 studies in Osteoarthritis with a site in Canada — 25 open to participants now, 46 under way, 4 of them phase 3. Osteoarthritis · Canada.

Planned enrollment
20th of 176
510 · median 98
Started
2024
with 3 others
No phase
101 of 205
16 open now
Primary completion
2027-03
later than 19 of 45 live
Registered
194th of 205
by date

Among the 205 studies in Osteoarthritis with a site in Canada, this one is the 20th largest by planned enrollment of the 176 interventional ones that give a count, is one of 4 that started in 2024, is one of 101 with no phase, reaches primary completion later than 19 of the 45 other live ones, and was the 194th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

25 of the 205 studies in Osteoarthritis with a site in Canada are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 14 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Osteoarthritis with a site in Canada, or all of them as a file.
02

Study summary

From 2014-2017, across 7 Canadian and 2 European sites, we randomized 618 patients at high-risk of re-injury, to anterior cruciate ligament reconstruction (ACLR) with or without a lateral extraarticular tenodesis (LET) and demonstrated that the addition of the LET reduced the risk of instability (RRR=0.38; 95% Confidence Interval (CI), 0.21-0.52; P=0.0001) and graft re-rupture (RRR, 0.67; 95% CI, 0.36-0.83; P=0.001). As a result, practice has changed; there has been a large increase in the proportion of orthopaedic surgeons recommending the addition of an LET at the time of ACLR and an increase in the number of patients requesting an LET from their surgeon. There is some weak evidence suggesting that in the longer term, the LET may increase the risk of developing osteoarthritis (OA) in that knee. Knee OA affects over 4.4 million Canadians and the number of younger adults being diagnosed with knee OA is growing and is a primary reason for seeking healthcare in Canada. The impact of OA in Canada is enormous and projected to cost Canada $17.5 billion annually in lost productivity alone by 2031. This study will use imaging and patient-reported Knee Outcomes Osteoarthritis Score (KOOS) to evaluate the incidence of OA at 10-years post ACL reconstruction with and without LET. We will also collect information about overall knee health, patient-reported outcomes, costs associated with knee injury, rehabilitation and disability, clinical failure, functional ability, and sport participation. It is crucial that we understand the risks of developing knee OA associated with the addition of an LET to an ACLR so that surgeons and patients can make informed decisions, not just for their immediate post injury treatment of the failed ligament, but for the potential long-term consequences of that decision.

03

Conditions studied

  • LET
  • ACL Reconstruction
  • Osteoarthritis (OA) of the Knee

Keywords

  • ACL
  • ACL injuries
  • ACL reconstruction
  • LET
  • Osteoarthritis
  • Knee osteoarthritis
  • Orthopaedics
  • Anterolateral ligament
  • Lateral Extra-articular Tenodesis (LET)
04

Who can participate

Ages eligible
14 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ACL deficient knee
  • skeletally mature to 25 years of age
  • 2 or more of:

    • competitive pivoting sport
    • grade 2 pivot shift or greater
    • generalized ligament laxity - Beighton score of 4 or greater

Exclusion criteria

Exclusion criteria:

  • previous ACL reconstruction on either knee
  • multi-ligament injury (two or more ligaments requiring surgical attention)
  • symptomatic articular cartilage defect requiring treatment other than debridement
  • greater than 3 degrees of asymmetric varus
  • unable to complete outcome questionnaires
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
510 participants (estimated)

Study arms

  • Active comparator
    ACL Reconstruction

    Standard ACL reconstruction only.

    Procedure: ACL Reconstruction

  • Experimental
    ACL + LET

    Anatomic ACL reconstruction following the same procedure as the active comparator group with an added lateral extra-articular tenodesis (LET).

    Procedure: Lateral Extra-Articular Tenodesis (LET) · Procedure: ACL Reconstruction

Interventions

  • ProcedureLateral Extra-Articular Tenodesis (LET)

    Lateral extra-articular tenodesis: A 1cm wide x 8cm long strip of iliotibial band is fashioned, leaving the Gerdys tubercle attachment intact. The graft is tunneled under the fibular collateral ligament (FCL) and attached to the femur with a Richards' staple (Smith \& Nephew), just distal to the intermuscular septum, proximal to the femoral insertion of the FCL. Fixation is performed with the knee at 70 degrees flexion, neutral rotation. Minimal tension is applied to the graft. The free end is then looped back onto itself and sutured using the No. 1 vicryl.

  • ProcedureACL Reconstruction

    Anatomic ACL reconstruction using a four-strand autologous hamstring graft. If the diameter of the graft is found to be less than 7.5mm, semitendinosus will be tripled (5 strand graft) providing a greater graft diameter. Femoral tunnels will be drilled using an anteromedial portal technique, with femoral fixation provided by an Endobutton or equivalent. Tibial fixation will be provided by interference screw.

06

What researchers measure

Primary outcomes

  1. Lateral compartment knee OA

    As was conducted at baseline and two years postoperative in the Stability 1 study, patients will undergo a standing semi-flexed posterior to anterior (PA) radiograph of both knees.

    Time frame: 10 Years

  2. Region-specific quality of life using the Knee Osteoarthritis and outcomes Score (KOOS)

    The KOOS is a 42-item knee-specific questionnaire with five separately reported domains, including pain (9 items), other symptoms (7 items), function in daily living (17 items), function in sports/recreation (5 items) and knee-related quality of life (4 items). Domain scores represent the average of all items in the domain standardized to a score from 0 to 100 (worst to best). This instrument has face validity and has demonstrated construct validity, excellent test-retest reliability for each domain (range, 0.75 to 0.93) and has been shown to be responsive to change in patients undergoing ACLR.

    Time frame: 10 Years

Secondary outcomes

  1. Disease-specific quality of life using the ACL Quality of Life Questionnaire (ACL-QOL)

    The ACL-QOL has five domains that query physical symptoms, occupational concerns, recreational activities, lifestyle, and social and emotional aspects. Each item has one 100 mm visual analogue scale response option, with labeled anchors at 0 mm (e.g., extremely difficult) and 100 mm (e.g., not difficult at all). Scores are calculated by converting the average of each of the five domain scores to a total average score out of 100% where 100% represents the best possible score.

    Time frame: 10 Years

  2. The Marx Activity Rating Scale (MARS)

    The MARS Activity Rating Scale is a four-item activity rating scale. The patient is asked to rate how often they were able to perform each activity (e.g. running, cutting, decelerating, and pivoting) in their most healthy and active state. The patient is provided with five categories of frequency of each functional activity, ranging from less than one time in a month to four or more times in a week. One point is allocated for each category of frequency and a maximum score of 16 points can be awarded. The MARS has demonstrated excellent test-retest reliability and construct validity in patients with disorders of the knee.

    Time frame: 10 Years

  3. Subjective symptoms, function and activity (IKDC)

    The International Knee Documentation Committee Subjective Knee Form (IKDC) is a knee-specific functional outcome that consists of 18-items about symptoms (7 items), sports activities (10 items) and function (1 item). Likert scales, a dichotomized item and 11 point rating scales make up the response options, and total score ranges from 0 (total limitation) and 100 (no limitations). The IKDC has shown test-retest reliability and good construct validity in patients with issues at the knee.

    Time frame: 10 Years

  4. MRI

    MRI will be performed only on patients recruited from the lead site at the Fowler Kennedy Sport Medicine Clinic (n=196). Similar to the imaging protocol used at the two-year visit, patients will undergo bilateral 3 Tesla MRI on a Siemens Magneton Trio magnet, and a 15-channel Siemens PRISMA knee coil at the 10-year visit. Longer T1rho and T2 relaxation times have shown to be associated with worsening cartilage quality. These changes can also be seen prior to the development of radiographic changes of OA, therefore, MRI can be used as a method for early detection of degenerative changes. The high incidence of arthritic changes observable at the 10 year time point using MRI (compared to plain radiographs), justifies the use of MRI in the subgroup of patients at the lead site.

    Time frame: 10 Years

  5. Patient Reported Quality of Life (ACL QOL)

    The ACL-QOL has five domains that query physical symptoms, occupational concerns, recreational activities, lifestyle, and social and emotional aspects. Each item has one 100 mm visual analogue scale response option, with labeled anchors at 0 mm (e.g., extremely difficult) and 100 mm (e.g., not difficult at all). Scores are calculated by converting the average of each of the five domain scores to a total average score out of 100% where 100% represents the best possible score. The ACL-QOL has demonstrated validity in patients with ACL injury and responsiveness to change in patients following ACLR.

    Time frame: 10 Years

  6. 4-Item Pain Intensity Measure (P4)

    Four-item questionnaire that asks patients to report the amount of pain they experience throughout the day (morning, afternoon, evening) and with activity. Each item response is a visual analog scale ranging from 0 (no pain) to 10 (as bad as it can be). The total score is a sum of the four responses to a maximum score of 40. The P4 has demonstrated good test-retest reliability and the ability to detect changes in pain intensity in patients with muscle and joint injuries. Because men and women may experience and report pain differently, we have included the Gender Role Expectation of Pain questionnaire to examine its association with pain and quality of life reporting in this study.

    Time frame: 10 Years

  7. Clinical Failure

    As previously described, clinical failure is defined as a composite of symptomatic instability requiring revision ACL surgery, or symptomatic instability with positive pivot shift, or asymmetrical pivot shift greater than the contralateral side.

    Time frame: 10 Years

  8. Objective Functional Measures

    Range of motion (ROM) measurement will include passive knee extension and active-assisted knee flexion. For passive knee extension, the patient is seated with legs extended on a table, heel propped so that the calf and upper thigh clear the treatment table. We will instruct the patient to relax both quadriceps and hamstrings to assure passive measurement. For active assisted knee flexion, the patient is seated with both legs extended on a table. We will instruct them to perform active-assisted knee flexion by placing one hand under their thigh to initiate flexion and then clasp both hands just below the tibial tuberosity. We will measure flexion and extension in degrees using a goniometer. For both measurements, we will centre the fulcrum of the goniometer over the lateral epicondyle of the femur. We will then align the stationary arm of the goniometer with the greater trochanter of the femur and the moving arm with the lateral malleolus at the ankle.

    Time frame: 10 Years

  9. Adverse Events

    We will record adverse events including painful hardware, graft rupture, and reasons for re-operation (e.g., painful knee joint, meniscal injuries, ACLR revision, contralateral ACLR, etc.). Given the significance of these types of events, we expect excellent recall.

    Time frame: 10 Years

07

Study locations

8 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Mar 2027, 28 months after the start.

Of 578 non-industry interventional studies with no phase under Osteoarthritis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 28 months is close to that.

Counting every sponsor, half of 713 studies reached it within 28 months; a quarter within 11 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2025
First posted
Mar 20, 2025
StartActual
Nov 1, 2024
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06885372
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Sponsor
First posted
Mar 20, 2025
Start date
Nov 1, 2024
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
May 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion